Background And Aim Of The Study: During recent years, pericardial bioprostheses have gained widespread acceptance as cardiac valve substitutes. The study aim was to evaluate the early clinical and hemodynamic performance of the Sorin SopranoTM supra-annular aortic bioprosthesis, as used for aortic valve replacement (AVR).
Methods: Between January 2004 and August 2006, a total of 501 patients (55% males; mean age 75 +/- 6.4 years) was prospectively enrolled into the study, which involved 10 European institutions. The indications for AVR were aortic stenosis in 91% of patients, aortic incompetence in 8%, and redo surgery in 1%. Preoperatively, 62% of the patients were in NYHA class III, and 12% in class IV. The mean prosthesis size was 21.4 +/- 1.8 mm. A non-everting technique was used in 88% of patients. Concomitant procedures were performed in 52% of cases (mainly coronary artery bypass grafts; 41%). The mean cross-clamp and cardiopulmonary bypass times were 70 +/- 27.2 min and 99 +/- 39.7 min, respectively. Doppler echocardiography performed at one and 12 months after surgery was evaluated by an independent core laboratory.
Results: Postoperatively, there were 25 early deaths (5%) and 13 late deaths, with an overall survival at one year of 92.9% (95% CI: 90.2-94.8) and freedom from valve-related death of 98.6% (95% CI: 97.5-99.6). After 12 months, most patients (87%) were in NYHA classes I-II. Actuarial freedoms from thromboembolism, bleeding, endocarditis and paraprosthetic leak at one year were 97.1% (CI: 95.1-98.2), 98.9% (CI: 97.4-99.5), 99.1% (CI: 97.7-99.7), and 99.6% (CI: 98.3-99.9), respectively. No events of thrombosis and structural valve deterioration (SVD) were observed. Subsequent echocardiographic evaluation showed low mean (11.1 +/- 5.1 mmHg at one year) and peak (19.5 +/- 8.9 mmHg at one year) transvalvular gradients, and a significant reduction in left ventricular mass, from 211 +/- 78.5 g at one month to 185 +/- 64.7 g at 12 months (p <0.0001).
Conclusion: After 12 months, the clinical outcome with the Soprano bioprosthesis, when used for AVR, was excellent. The bioprosthesis also showed good hemodynamic performance, with a significant reduction of left ventricular hypertrophy.
Download full-text PDF |
Source |
---|
Eur Heart J Digit Health
January 2025
Department of Cardiovascular Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Aims: Aortic stenosis (AS) is a common and progressive disease, which, if left untreated, results in increased morbidity and mortality. Monitoring and follow-up care can be challenging due to significant variability in disease progression. This study aimed to develop machine learning models to predict the risks of disease progression and mortality in patients with mild AS.
View Article and Find Full Text PDFEur Heart J Digit Health
January 2025
Cardiology Department, Dr Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), C/Maestro Alonso s/n, Alicante 03010, Spain.
Aims: Evidence regarding the safety of early discharge following transcatheter aortic valve implantation (TAVI) is limited. The aim of this study was to evaluate the safety of very early (<24) and early discharge (24-48 h) as compared to standard discharge (>48 h), supported by the implementation of a voice-based virtual assistant using artificial intelligence (AI) and natural language processing.
Methods And Results: Single-arm prospective observational study that included consecutive patients who underwent TAVI in a tertiary hospital in 2023 and were discharged under an AI follow-up programme.
Hosp Pharm
January 2025
Division of General Internal Medicine, Department of Medicine, Center for Research in Healthcare, University of Pittsburgh, Pittsburgh PA, USA.
We describe a case of a 67-year-old man with bioprosthetic aortic valve endocarditis secondary to , a rare Gram-negative plant pathogen. The initial source was assumed to be due to soil exposure. The patient was successfully managed with ceftriaxone following aortic valve replacement.
View Article and Find Full Text PDFSurg Pract Sci
June 2023
Cardiovascular Research & Innovation, School of Medicine, University of Galway, Galway, Ireland.
Higher and prohibitive mitral valve disease surgical scenarios are preferred cases for transcatheter mitral valve replacement as they offer unrelenting mitral valve regurgitation reduction. This review entails medical technologies that are evolving bioprosthetic devices for mitral valve repair and replacement purposes. Transcatheter mitral valve replacement is compared with transcatheter aortic valve implantation based on the etiology and driving factors.
View Article and Find Full Text PDFRadiol Case Rep
March 2025
Department of Medical Imaging, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia.
Subclavian artery pseudoaneurysm (SAP) is a rare but lethal diagnosis, and an important condition that should be detected and managed imperatively. SAP has been seldom described in the literature, explaining the lack of concrete management guidelines. Herein we present a case study of a 63-year-old man with SAP post a transcatheter aortic valve implantation (TAVI) done 8 days prior to current presentation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!